Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indisulam + Capecitabine in Metastatic Colorectal Cancer
NCT00165854Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2003
- Modality
- RNA-Targeting Small Molecules, Molecular Glues
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of indisulam in metastatic colorectal cancer (mCRC), sponsored by Eisai Co., Ltd. Primary endpoints: Recommended Dose of E7070 in combination with capecitabine, Safety and Tolerability and 2 more. Started Mar 2003; status: completed.
02
Drugs
indisulam
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00165854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165854.